Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:13:19.393Z.
Calculation as of: 2026-10-06T19:13:19.393Z.
Quote observation: 2026-10-06T19:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cae73e0f7d7453288b6b30bb28ae33caa2dcc4a3490ac3f0933bc7bc3ce0e433
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-03-31.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.89B
EV/Sales Ratio
18.27x
TTM Avg
14.52x
3Y Avg
11.97x
5Y Avg
10.42x
Market Cap
$1.85B
EV/Sales Ratio
0.63x
TTM Avg
0.66x
3Y Avg
0.99x
5Y Avg
1.19x
Market Cap
$1.90B
EV/Sales Ratio
18.66x
TTM Avg
32.21x
3Y Avg
52.53x
5Y Avg
140.66x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.87B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.86B | 2.81x | 1.90x | 2.97x | 4.80x |
| Zymeworks Inc. (ZYME)vs › | $1.88B | 53.16x | 22.33x | 13.89x | 12.70x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 18.27x | 14.52x | 11.97x | 10.42x |
| Immunome, Inc. (IMNM)vs › | $1.89B | N/A | 219.89x | 101.44x | 93.82x |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 0.63x | 0.66x | 0.99x | 1.19x |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.90B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | 18.66x | 32.21x | 52.53x | 140.66x |
| Novavax, Inc. (NVAX)vs › | $1.83B | 4.67x | 2.05x | 1.43x | 3.18x |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | 8.59x | 10.77x | 8.72x | 9.74x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2025-03-31 | 13.54x |
| 2025-03-28 | 13.65x |
| 2025-03-27 | 13.30x |
| 2025-03-26 | 13.48x |
| 2025-03-25 | 12.80x |
| 2025-03-24 | 13.41x |
| 2025-03-21 | 13.69x |
| 2025-03-20 | 12.97x |
| 2025-03-19 | 13.15x |
| 2025-03-18 | 13.40x |
| 2025-03-17 | 13.04x |
| 2025-03-14 | 13.01x |
| 2025-03-13 | 12.71x |
| 2025-03-12 | 14.56x |
| 2025-03-11 | 13.54x |
| 2025-03-10 | 10.66x |
| 2025-03-07 | 10.04x |
| 2025-03-06 | 9.42x |
| 2025-03-05 | 7.80x |
| 2025-03-04 | 6.13x |
| 2025-03-03 | 4.96x |
| 2025-02-28 | 4.78x |
| 2025-02-27 | 4.25x |
| 2025-02-26 | 4.20x |
| 2025-02-25 | 4.72x |
| 2025-02-24 | 5.41x |
| 2025-02-21 | 4.62x |
| 2025-02-20 | 4.40x |
| 2025-02-19 | 6.40x |
| 2025-02-18 | 6.42x |
| 2025-02-14 | 4.96x |
| 2025-02-13 | 5.42x |
| 2025-02-12 | 2.25x |
| 2025-02-11 | 1.51x |
| 2025-02-10 | 1.07x |
| 2025-02-07 | 0.90x |
| 2025-02-06 | 0.34x |
| 2025-02-05 | 0.09x |
| 2025-01-07 | 0.06x |
| 2025-01-06 | 0.09x |
| 2024-12-12 | 1.48x |
| 2024-12-11 | 1.96x |
| 2024-12-10 | 2.37x |
